Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Radiol ; 69(9): 952-8, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24957853

RESUMO

AIM: To gather information in order to highlight areas within training that could be improved and share ideas of good practice and, in addition, to compare national results with those of local training schemes. MATERIALS AND METHODS: A request to participate in the survey was emailed to 1158 radiology trainees across 36 UK training schemes in October 2012. The electronic replies were anonymous. The survey remained active for 6 weeks. The data were collated and analysed by members of the JRF. The survey itself was divided into seven sections, covering a diverse range of topics. RESULTS: Six hundred and four trainees from 36 UK training schemes completed the survey, resulting in a response rate of 52%.


Assuntos
Competência Clínica , Educação de Pós-Graduação em Medicina/estatística & dados numéricos , Sistemas de Informação em Radiologia/estatística & dados numéricos , Radiologia/educação , Atitude do Pessoal de Saúde , Coleta de Dados , Educação Médica Continuada , Feminino , Humanos , Internato e Residência , Masculino , Avaliação de Programas e Projetos de Saúde , Inquéritos e Questionários , Reino Unido
2.
J Assoc Physicians India ; 45(4): 283-5, 1997 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12521085

RESUMO

The aim of the study was to evaluate the role of ascitic fluid fibronectin in the diagnosis of malignant ascites. Fibronectin is a glycoprotein which plays an important role in regulating the organisation of the cell cytoskeleton and cell morphology. Ascitic fluid samples from 35 patients, 20 with portal hypertension (Group-I) and 15 with malignant ascites (Group-II) were analysed for proteins, cell counts, fibronectin levels and malignant cell cytology. Mean ascitic fluid fibronectin level was found to be significantly higher in malignant ascites as compared to portal hypertension (p < 0.001). At a cut off value of 94.67 microg/ml, the sensitivity, specificity, positive accuracy, negative accuracy and overall diagnostic accuracy was found to be 100%, 95%, 93.8%, 100% and 97.1% respectively.


Assuntos
Ascite/diagnóstico , Ascite/imunologia , Líquido Ascítico/química , Fibronectinas/análise , Neoplasias Peritoneais/diagnóstico , Neoplasias Peritoneais/imunologia , Adulto , Líquido Ascítico/imunologia , Feminino , Fibronectinas/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Reprodutibilidade dos Testes
3.
J Assoc Physicians India ; 44(11): 784-5, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9251453

RESUMO

Most hepatic hemangiomas are small and symptomless. These are now being increasingly diagnosed with the greater use of scanning procedures. Hemangiomas can occasionally grow to a large size and become manifest to the patient and the clinician. Giant hemangiomas can produce symptoms including awareness of abdominal mass, pain due to thrombosis, and very rarely, rupture. Though ultrasound is known to be quite suggestive of the diagnosis, large hemangiomas may be mistaken for liver metastases due to their enormous size and variegated picture on the scanning procedure. Dynamic CT scan and at times MRI may be required for confirmation of the diagnosis. Needle biopsy is contraindicated if the diagnosis is suspected.


Assuntos
Hemangioma Cavernoso/diagnóstico , Neoplasias Hepáticas/diagnóstico , Adulto , Idoso , Diagnóstico Diferencial , Feminino , Humanos , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade
4.
Indian J Gastroenterol ; 15(3): 97-8, 1996 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8840635

RESUMO

Pneumatic dilatation and surgery are equally effective in the treatment of achalasia cardia but carry some risk of complications. We report our initial experience with the use of botulinum toxin in the treatment of achalasia. Six of seven patients treated responded, with improvement lasting till the end of follow-up at 3 months. No adverse effect was observed.


Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Acalasia Esofágica/terapia , Fármacos Neuromusculares/uso terapêutico , Adulto , Transtornos de Deglutição/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA